tiprankstipranks
Advertisement
Advertisement

CGEM Stock Latest News

Cullinan, Taiho say results of Phase 3 trial selected for presentation
The FlyCullinan, Taiho say results of Phase 3 trial selected for presentation
10d ago
CGEM
Analyst Reiterates Buy on Cullinan as Zipalertinib Progress Supports NDA Path; $30 Price Target Maintained
PremiumRatings
Analyst Reiterates Buy on Cullinan as Zipalertinib Progress Supports NDA Path; $30 Price Target Maintained
12d ago
CGEM
Taiho, Cullinan Therapeutics study demonstrates statistically significant PFS
PremiumThe Fly
Taiho, Cullinan Therapeutics study demonstrates statistically significant PFS
12d ago
CGEM
Cullinan Therapeutics price target raised to $47 from $46 at Clear Street
PremiumThe Fly
Cullinan Therapeutics price target raised to $47 from $46 at Clear Street
12d ago
CGEM
Strong Phase III Zipalertinib Data and Taiho Partnership Drive Matt Phipps’ Buy Rating on Cullinan for Favorable Risk‑Reward
PremiumRatings
Strong Phase III Zipalertinib Data and Taiho Partnership Drive Matt Phipps’ Buy Rating on Cullinan for Favorable Risk‑Reward
16d ago
CGEM
Cullinan Reports Positive Phase 3 Zipalertinib Lung Cancer Data
PremiumCompany AnnouncementsCullinan Reports Positive Phase 3 Zipalertinib Lung Cancer Data
16d ago
8K
CGEM
Cullinan Oncology: Buy Rating Reaffirmed with Unchanged $30 Price Target on Robust Pipeline and Strong Cash Position
Premium
Ratings
Cullinan Oncology: Buy Rating Reaffirmed with Unchanged $30 Price Target on Robust Pipeline and Strong Cash Position
19d ago
CGEM
Cullinan Maintained at Buy as Rich Clinical Pipeline and Regulatory Momentum Support Unchanged $33 Price Target
Premium
Ratings
Cullinan Maintained at Buy as Rich Clinical Pipeline and Regulatory Momentum Support Unchanged $33 Price Target
22d ago
CGEM
Cullinan Maintained at Buy as Advancing Autoimmune and Oncology Pipeline Supports Unchanged $36 Price Target
PremiumRatings
Cullinan Maintained at Buy as Advancing Autoimmune and Oncology Pipeline Supports Unchanged $36 Price Target
22d ago
CGEM
Cullinan Therapeutics reports Q2 EPS (81c), consensus (85c)
PremiumThe Fly
Cullinan Therapeutics reports Q2 EPS (81c), consensus (85c)
23d ago
CGEM
Cullinan Therapeutics Launches Early Trial of Velinotamig in Hard‑to‑Treat Blood Disorders
PremiumCompany Announcements
Cullinan Therapeutics Launches Early Trial of Velinotamig in Hard‑to‑Treat Blood Disorders
29d ago
CGEM
Cullinan Therapeutics price target raised to $39 from $38 at BTIG
PremiumThe Fly
Cullinan Therapeutics price target raised to $39 from $38 at BTIG
1M ago
CGEM
Analyst Reiterates Buy on CGEM as CLN-049 Advances Toward Registrational Phase 2; Price Target Raised to $39 on Improved Risk-Reward
PremiumRatingsAnalyst Reiterates Buy on CGEM as CLN-049 Advances Toward Registrational Phase 2; Price Target Raised to $39 on Improved Risk-Reward
1M ago
CGEM
Cullinan Therapeutics announces End-of-Phase 1 meeting for CLN-049 with FDA
Premium
The Fly
Cullinan Therapeutics announces End-of-Phase 1 meeting for CLN-049 with FDA
1M ago
CGEM
Cullinan Therapeutics management to meet with BTIG
Premium
The Fly
Cullinan Therapeutics management to meet with BTIG
2M ago
CGEM
Cullinan Therapeutics Shareholders Back Directors and Governance Measures
PremiumCompany Announcements
Cullinan Therapeutics Shareholders Back Directors and Governance Measures
2M ago
8K
CGEM
Cullinan Therapeutics price target raised to $46 from $33 at Clear Street
PremiumThe Fly
Cullinan Therapeutics price target raised to $46 from $33 at Clear Street
3M ago
CGEM
Cullinan Therapeutics Highlights Positive Early Autoimmune Trial Data
PremiumCompany Announcements
Cullinan Therapeutics Highlights Positive Early Autoimmune Trial Data
3M ago
8K
CGEM
Cullinan Therapeutics reports CLN-978, velinotamig data
PremiumThe Fly
Cullinan Therapeutics reports CLN-978, velinotamig data
3M ago
CGEM
Buy Rating on Cullinan Reinforced by Encouraging Early CLN-978 Autoimmune Data and High Upside Potential
PremiumRatingsBuy Rating on Cullinan Reinforced by Encouraging Early CLN-978 Autoimmune Data and High Upside Potential
3M ago
CGEM
Cullinan Showcases Promising CLN-978 Phase 1 Autoimmune Data
Premium
Company Announcements
Cullinan Showcases Promising CLN-978 Phase 1 Autoimmune Data
3M ago
8K
CGEM
Cullinan Therapeutics Reiterated as Buy on Promising CLN-978 Data; $30 Price Target Maintained
Premium
Ratings
Cullinan Therapeutics Reiterated as Buy on Promising CLN-978 Data; $30 Price Target Maintained
3M ago
CGEM

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >